Suppr超能文献

局部使用含布地奈德制剂后出现严重皮肤疹:是时候重新考虑其在澳大利亚的注册情况了吗?

Severe cutaneous eruptions following the topical use of preparations containing bufexamac: Is it time to reconsider its registration in Australia?

作者信息

Harris Adam G, Saikal Samra L, Scurry Jim, Relic John, Nixon Rosemary L, Chee Paul

机构信息

Department of Dermatology, John Hunter Hospital, Newcastle, New South Wales, Australia.

Faculty of Medicine, University of Newcastle, Newcastle, New South Wales, Australia.

出版信息

Australas J Dermatol. 2019 Feb;60(1):53-56. doi: 10.1111/ajd.12910. Epub 2018 Aug 28.

Abstract

Despite being a well-recognised cause of allergic contact dermatitis with an embargo in many countries around the world, bufexamac is available over the counter in topical preparations in Australia. We present a series of patients who developed severe cutaneous eruptions after the topical application of bufexamac containing preparations to highlight the potential risks of this medication, as well as advocate for the reconsideration of its registration by the Therapeutic Goods Administration in Australia.

摘要

尽管布地奈德是一种在世界许多国家都被禁售的、公认的过敏性接触性皮炎病因,但在澳大利亚,含有布地奈德的外用制剂仍可在柜台购买。我们报告了一系列患者,他们在局部使用含布地奈德的制剂后出现了严重的皮肤疹,以强调这种药物的潜在风险,并主张澳大利亚治疗用品管理局重新考虑其注册情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验